Friedlander M L, Kearsley J H, Sims K, Coates A, Hedley D, Raghavan D, Fox R M, Tattersall M H
Aust N Z J Med. 1983 Feb;13(1):53-6. doi: 10.1111/j.1445-5994.1983.tb04550.x.
Twenty-seven consecutive patients were treated with 3 mg oral lorazepam and 2.5 mg intravenous haloperidol in an effort to improve patient tolerance of cytotoxic chemotherapy and decrease nausea and vomiting. Antiemetic efficacy and side-effects were assessed using a patient questionnaire. Vomiting either did not occur, or was considered to be of only moderate intensity in 22 patients (81%) and usually ceased within 24 hours of commencing chemotherapy. Similarly, nausea was either absent or of only moderate severity, lasting less than 48 hours in the majority of patients. Eight of 11 patients who had received similar previous cytotoxic treatment with antiemetic agents but not lorazepam considered that lorazepam and haloperidol had considerably improved their tolerance of chemotherapy. The side-effects of haloperidol and lorazepam were mild and well tolerated.
连续27例患者接受了口服3毫克劳拉西泮和静脉注射2.5毫克氟哌啶醇的治疗，目的是提高患者对细胞毒性化疗的耐受性，并减少恶心和呕吐。使用患者问卷评估止吐效果和副作用。22例患者（81%）未发生呕吐，或仅为中度呕吐，且通常在化疗开始后24小时内停止。同样，大多数患者恶心不存在或仅为中度严重程度，持续时间少于48小时。11例之前接受过类似细胞毒性治疗并使用过止吐药但未使用劳拉西泮的患者中，有8例认为劳拉西泮和氟哌啶醇显著提高了他们对化疗的耐受性。氟哌啶醇和劳拉西泮的副作用轻微，耐受性良好。
